+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06680596

Screening for Tumor DNA in HR, HER2 Low Metastatic Breast Cancer Patients Followed by Trastuzumab Deruxtecan Treatment for Persistent Tumor DNA

Led by UNICANCER · Updated on 2026-10-29

80

Participants Needed

40

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating treatments for patients with hormone receptor-positive, HER2 low or ultralow metastatic breast cancer who are undergoing first-line therapy with a CDK46 inhibitor combined with an aromatase inhibitor or fulvestrant. This open-label, multicenter phase II study focuses on patients whose tumor DNA remains detectable in their blood after four weeks of standard therapy, aiming to evaluate progression-free survival using trastuzumab deruxtecan T-DXd treatment. Patients first enter a screening phase to confirm the presence of circulating tumor DNA after starting standard treatment. Those with persistent tumor DNA are enrolled in the treatment phase, where they receive trastuzumab deruxtecan as an intravenous injection every three weeks at a dose of 5.4 mgkg. This single-group study evaluates how long patients live without disease progression while receiving the study drug. Participants undergo regular assessments including laboratory tests and imaging to monitor their disease status and safety during the study. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, clinical benefit, time to response, and treatment toxicity up to five years. Participants are followed for outcomes and safety throughout the study period, which may last several years.

CONDITIONS

Brief Title

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Research Team

F

François LEGRAND

M

Marta JIMENEZ

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here